Skip to main content
OpenTrials
Completed

NCT Number: NCT04456478

Impact of PH Values of the Embryo Culture Medium on Success of in Vitro Fertilization (IVF)

The objective of this study is to compare, through a multicentric randomized trial, the impact of two pH values in the embryo culture medium on the clinical results of In Vitro Fertilization (IVF) process and especially the impact on live birth delivery rate.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

CHU de BORDEAUX, Bordeaux, France

Loading trial locations.

About this study

Despite progress in Assisted Reproductive Technology (ART), the livebirth rate per oocyte retrieval during In Vitro Fertilization (IVF) remain relatively low (15 à 25%). This is in part due to the sensitivity of the preimplantation embryo to its environment. Indeed, there is growing evidence that culture conditions during IVF are critical not only for the development of pre- and post-implantation embryo, but also for long-term health effects; and numerous animal data suggest the importance of pH control in the IVF culture medium. Maintaining the intercellular pH (pHi) is one of the vital roles of embryo homeostasis since pHi regulates many cellular processes. Indeed, variations in pHi can affect embryonic development. Although the embryo has biochemical systems to regulate its pHi, these systems can be overtaken. Under the conditions of IVF embryo culture, the extracellular pH (pHe) in a culture medium is the result of a balance between CO2 concentration in the incubator and bicarbonate concentration in the culture medium (determined by the medium manufacturer). The recommendations of the manufacturers of embryo culture media are to maintain a pHe slightly higher (generally between 7.2 and 7.4) than the pHi (estimated between 7.1 to 7.2) to compensate for the acidification due to cell metabolism. However, as the pH scale is logarithmic, a pHe variation of 7.2 to 7.4 corresponds to a decrease in the concentration of H+ ions by a factor of 1.6 in the medium. Actually, there is no clinical data to know what is the ideal pH to apply to a culture medium during IVF.

This is a clinical study comparing two pH values in the culture medium of embryos obtained by IVF, randomized, multicentric (3 centers), patient-blinded, in groups parallel to the ratio 1: 1. IVF-ICSI will be performed according to the usual procedure and the day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the oocytes and embryos in the culture medium with a pH at 7.38 ± 0.02 or a pH at 7.22 ± 0.02.

In case of pregnancy after embryo transfer, patients will be followed until delivery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Couples whose woman is 18 to 40 years old and man is 18 to 60 at the time of inclusion.
  • Infertile couple with a medical indication of IVF-ICSI according to criteria applied in each center.
  • First or second ICSI attempt with fresh embryo transfer.
  • Signature of informed consent by both partners of the couple
  • Affiliation to a social security scheme or equivalent for both partners of the couple.
  • Fitting the inclusion criteria for IVF according the the French law.

Exclusion criteria

  • Use of spermatozoa extracted by testicular biopsy.
  • Freeze-al strategy (without fresh embryo transfer) decided before embryo culture
  • Absence of mature oocyte (metaphase II) at the day of the puncture
  • Uterine pathology affecting implantation (uterine malformation, diffuse adenomyosis ...)
  • One of the two partners (or both) is (are) infected with HIV, HCV or HBV in the year before the inclusion
  • One of the two partners (or both) is (are) in safeguarding justice, under guardianship or trusteeship.
  • Couple having already participated once in the study.
  • Couple enrolled in another interventional clinical study

Treatment and study plan

pH at 7.38 ± 0.02

Procedure

In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.

pH at 7.22 ± 0.02

Procedure

In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.

Primary outcomes

  1. Live birth delivery rate

    Time frame: month 9

    Number of deliveries that resulted in at least one live birth (gestational age ≥ 22 weeks) / Number of oocyte retrievals

Secondary outcomes

  1. Fertilization rate

    Time frame: day 1

    Number of 2PN zygotes at day 1 post-injection / Number of matures injected oocytes

  2. Cleavage rate

    Time frame: day 2

    Number of embryos with at least 2 blastomeres at day 2 / Number of diploid zygotes at day 1 post-injection

  3. Percentage of top embryos

    Time frame: day 3

    Number of 7 to 10-blastomeres embryos at day 3 with less than 10% fragments / Total number of embryos at day 3

  4. Embryo freezing rate

    Time frame: day 6

    Number of frozen embryos / Total number of obtained embryos

  5. Implantation rate

    Time frame: week 5

    Number of gestational sacs observed with ultrasonography (5 weeks after embryo transfer) divided by the number of embryos transferred (expressed as a percentage)

  6. Clinical ongoing pregnancy rate by transfer

    Time frame: week 5

    Number of pregnancies diagnosed by ultrasonographic of at least one fetus with a discernible heartbeat at 5 weeks after embryo transfer / Number of embryo transfers

  7. Clinical ongoing pregnancy rate by oocyte retrieval

    Time frame: week 5

    Number of pregnancies diagnosed by ultrasonographic of at least one fetus with a discernible heartbeat at 5 weeks after embryo transfer / Number of oocyte retrieval

  8. Miscarriage rate

    Time frame: week 22

    Number of spontaneous loss of an intrauterine pregnancy prior to 22 completed weeks of gestational age / Number of pregnancies

  9. Malformation rate diagnosed at birth

    Time frame: month 9

    Number of malformations according to Eurocat classification (in total and in Eurocat subgroups) / Total number of newborns

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Official study title

Randomized Trial in Assisted Reproductive Technology : Impact of PH Values of the Embryo Culture Medium on Live Birth Rate After in Vitro Fertilization (IVF)

Acronym: ACIDOFIV

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Jul 2, 2020
Registry last updated
Jan 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.